Maad Rayan Publishing Company Biomedical Research Bulletin 2980-9924 1 3 2023 09 29 Gender Differences in Response to Statin Therapy in Ischemic Stroke Patients With SLCO1B1 388A>G Polymorphism: A Clinical Study 96 104 10.34172/biomedrb.2023.19 EN Tayebeh Sabokbar https://orcid.org/0000-0003-4778-9822 Ehsan Sharifipour https://orcid.org/0000-0002-5793-3288 Masumeh Zamanlu https://orcid.org/0000-0002-6326-8448 Tahereh Komeili Movahhed https://orcid.org/0000-0002-2210-7541 Mohammad Aghaali https://orcid.org/0000-0003-3417-1580 Motahare Salarvand https://orcid.org/0000-0003-2756-823X Fariedoddin Javaherian https://orcid.org/0000-0002-7653-0724 Seyyed Amir Hejazi https://orcid.org/0000-0001-9378-3371 Journal Article 10.34172/biomedrb.2023.19 2023 09 03 2023 09 15 Background: Statins are widely used for the medical management of vascular conditions, including ischemic stroke. However, genetic factors and polymorphisms, including SLCO1B1 388A>G single-nucleotide polymorphism (SNP), have shown significant effects in response to statin therapy. To the best of our knowledge, gender-gene interaction in response to statin therapy, affected by the SLCO1B1 388 A>G SNP, has not been investigated yet. The current study describes the therapeutic outcomes of this variation in terms of clinical evaluations and laboratory parameters. Methods: Seventy patients diagnosed with acute ischemic stroke were recruited for this study. Blood samples were collected. The SLCO1B1 388A>G gene was genotyped using a polymerase chain reaction-restriction fragment length polymorphism method, and the three possible polymorphisms (388GG, 388GA, and 388AA) were detected accordingly. Statin treatment was prescribed at a dose of 40 mg of Atorvastatin or 20 mg of Rosuvastatin daily. Laboratory assessments, including a lipid profile, liver function tests, and lactate dehydrogenase, as well as clinical evaluations, including scores of stroke severity, were obtained at baseline and after a three-month follow-up. Results: Iranian ischemic stroke patients showed all three possible polymorphisms, including 30 patients with AA, 28 patients with AG, and 12 patients with GG. Significant SNP variations and gender-gene interactions for most measures of the lipid profile and some clinical trends were found in such a manner that the GG genotype was associated with relevant resistance to statin treatment, while the AA genotype, particularly in male patients, was associated with more response to statin treatment. Conclusion: This investigation adds influential gender differences to the previously reported SLCO1B1 388A>G SNP-induced variations of statin therapeutic response in stroke patients.